Page last updated: 2024-09-05

sorafenib and losartan

sorafenib has been researched along with losartan in 9 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(losartan)
Trials
(losartan)
Recent Studies (post-2010) (losartan)
6,5207305,2517,2311,2452,118

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)losartan (IC50)
Bile salt export pumpHomo sapiens (human)9.01
Cytochrome P450 2C9 Homo sapiens (human)2.882
Angiotensin-converting enzyme Homo sapiens (human)0.019
Atrial natriuretic peptide receptor 3Homo sapiens (human)0.0018
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.019
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)0.0247
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)0.0234
Adenosine receptor A2aRattus norvegicus (Norway rat)0.0032
Type-1 angiotensin II receptorHomo sapiens (human)0.047
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)0.025
Type-2 angiotensin II receptorRattus norvegicus (Norway rat)0.0118
Type-2 angiotensin II receptorHomo sapiens (human)0.019
Platelet glycoprotein VIHomo sapiens (human)4
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)1.1481
Type-1 angiotensin II receptorCavia porcellus (domestic guinea pig)0.018
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.2884

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (66.67)24.3611
2020's3 (33.33)2.80

Authors

AuthorsStudies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Aihara, Y; Douhara, A; Fukui, H; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Yoshiji, H1
Carter, JJ; Fretwell, LV; Woolard, J1
Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S1
Abdelgalil, AA; Ahamad, SR; Al-Jenoobi, FI; Mohamed, OY1
Gillani, TB; Murray, M; Nair, PC; Rawling, T1

Reviews

2 review(s) available for sorafenib and losartan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022

Other Studies

7 other study(ies) available for sorafenib and losartan

ArticleYear
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index

2014
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
    Journal of gastroenterology, 2014, Volume: 49, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Precancerous Conditions; Rats, Inbred F344; Sorafenib

2014
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017, Volume: 31, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides

2017
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
    Toxicology letters, 2018, Oct-01, Volume: 295

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2018
The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat.
    European journal of pharmacology, 2020, Sep-05, Volume: 882

    Topics: Animals; Antineoplastic Agents; Cardiotonic Agents; Cardiotoxicity; Heart; Heart Rate; Losartan; Male; Metabolomics; Myocardium; Protein Kinase Inhibitors; Rats, Wistar; Sorafenib

2020
Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite.
    Chemico-biological interactions, 2021, Apr-01, Volume: 338

    Topics: Adult; Biotransformation; Catalytic Domain; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Humans; Losartan; Male; Metabolome; Microsomes, Liver; Middle Aged; Molecular Docking Simulation; Oxidation-Reduction; Oxides; Sorafenib; Substrate Specificity

2021